Rilonacept Regeneron

Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

1 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
ANNEX I 

 
SUMMARY OF PRODUCT CHARACTERISTICS 

 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

2 

1. NAME OF THE MEDICINAL PRODUCT 
 
Rilonacept Regeneron 80 mg/ml powder and solvent for solution for injection. 
 
 
2. QUALITATIVE AND QUANTITATIVE COMPOSITION 
 
Each vial of powder contains 220 mg of rilonacept. After reconstitution, each ml of solution contains 80 
mg rilonacept. 
  
For the full list of excipients, see section 6.1. 
 
 
3. PHARMACEUTICAL FORM 
 
Powder and solvent for solution for injection. 
 
The powder is white to off-white. 
The solvent is a clear colourless solution.  
 
 
4. CLINICAL PARTICULARS 
 
4.1 Therapeutic indications 
 
Rilonacept Regeneron is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) 
with severe symptoms, including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells 
Syndrome (MWS), in adults and children aged 12 years and older. 
 
4.2 Posology and method of administration 
 
Treatment should be initiated and supervised by a specialist physician experienced in the diagnosis and 
treatment of CAPS. 
 
After proper training in the correct injection technique, patients may self-inject Rilonacept Regeneron if 
their physician determines that it is appropriate and with medical follow-up as necessary. 
 
Posology 
Adults 
Treatment in adults should be initiated with a loading dose of 320 mg. Dosing should be continued with a 
once-weekly injection of 160 mg. Rilonacept Regeneron should not be given more often than once 
weekly.  
 
Paediatric population (12 to 17 years old) 
Treatment should be initiated with a loading dose of 4.4 mg/kg, up to a maximum of 320 mg. Dosing 
should be continued with a once-weekly injection of 2.2 mg/kg, up to a maximum of 160 mg (see Table 
1).  Dosing in children must be adjusted as the child grows. The patient or care giver should be advised to 
speak to the treating physician before adjusting the dose. The experience in children is limited. In the 
clinical program for CAPS, 8 adolescents aged 12-17 were treated for up to 18 months. 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

3 

Paediatric population (up to 12 years old) 
No data are available on the use of Rilonacept Regeneron in children with CAPS under 12 years of age, 
therefore it is not recommended in this paediatric age group. 
 
Elderly (65 years old or older) 
Available data indicate that dose modification is not required based on advanced age. However, clinical 
experience in patients above 65 years is limited, therefore caution is recommended (see section 5.1). 
 
Renal impairment 
No dose adjustment is required in patients with mild, moderate, or severe renal impairment, or end stage 
renal disease. However, clinical experience in such patients is limited. 
 
Hepatic impairment 
Rilonacept Regeneron has not been studied in patients with hepatic impairment. 
 
Method of administration 
Rilonacept Regeneron is for subcutaneous use only.  It is not intended for intravenous or intramuscular 
use. 
For instructions on reconstitution of the medicinal product before administration, see section 6.6.  
 
The adult loading dose should be administered as two 2 ml subcutaneous injections (320 mg of rilonacept 
in total) given on the same day at different sites. The subsequent doses are administered as a 2 ml (160 mg 
of rilonacept) subcutaneous injection once a week. 
 
For paediatric patients, the dose is delivered as one or two (for loading dose) subcutaneous injections with 
a maximum single-injection volume of 2 ml. 
 
For convenience, the corresponding dose volume for weekly injection in paediatric patients is presented in 
Table 1 below.  
 
Table 1:  Rilonacept Regeneron dose volume (after reconstitution) by body weight for paediatric patients 
aged 12-17 years 
 

Weight range (kg) Dose volume (ml) 
23.6 to 27.2  0.7 
27.3 to 30.8 0.8 
30.9 to 34.4  0.9 
34.5 to 38.1  1 
38.2 to 41.7  1.1 
41.8 to 45.4  1.2 
45.5 to 49.0  1.3 
49.1 to 52.6  1.4 
52.7 to 56.3  1.5 
56.4 to 59.9  1.6 
60.0 to 63.5  1.7 
63.6 to 67.2 1.8 
67.3 to 70.8  1.9 

70.9 or greater 2 

 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

4 

4.3 Contraindications 
 
Hypersensitivity to rilonacept or to any of the excipients.  
Active, severe infections (see section 4.4). 
 
4.4 Special warnings and precautions for use 
 
Serious infections 
Interleukin-1 (IL-1) blockade may interfere with immune response to infections. Serious, life-threatening 
infections have been reported uncommonly in patients taking Rilonacept Regeneron.  
 
In an open-label extension study, one patient developed bacterial meningitis and died. Rilonacept 
Regeneron should be discontinued if a patient develops a serious infection. Treatment should not be 
initiated in patients with an active or chronic infection (see section 4.3) and physicians should exercise 
caution when administering Rilonacept Regeneron to patients with a history of recurring infections or with 
underlying conditions that may predispose them to infections. 
 
Because Rilonacept Regeneron dampens an inflammatory response, vigilance in excluding underlying 
infection in unwell patients is required. 
 
Tumour necrosis factor (TNF) inhibitors have been associated with an increased risk of reactivation of 
latent tuberculosis (TB). It is unknown whether the use of IL-1 inhibitors like rilonacept increases the risk 
of reactivation of TB or of opportunistic infections.  Before starting treatment with Rilonacept Regeneron, 
all patients should be evaluated for both active and inactive (latent) tuberculosis.  
 
Combinations not recommended  
The combination of Rilonacept Regeneron with TNF inhibitors has not been evaluated in clinical studies. 
An increased incidence of serious infections has been associated with administration of another IL-1 
inhibitor, in combination with a TNF inhibitor.  
 
Rilonacept Regeneron should not be used with TNF inhibitors because of increased risk of serious 
infections (see section 4.5).  
 
The concomitant use of Rilonacept Regeneron with other IL-1 inhibitors is not recommended (see section 
4.5).  
 
Hypersensitivity 
Although hypersensitivity reactions related to treatment with Rilonacept Regeneron were not seen in the 
initial clinical program, if a hypersensitivity reaction occurs, administration should be stopped 
immediately and permanently, and appropriate therapy initiated. 
 
The risk for severe hypersensitivity reactions, which is not uncommon for injectable proteins, cannot be 
excluded (see section 4.3). 
 
Immunogenicity 
Antibodies directed against the receptor domains of rilonacept were detected by an ELISA assay in 35% 
of patients (19 out of 55) treated for at least 6 weeks in the clinical study. There was no correlation of 
antibody activity with either clinical efficacy or safety. 
 
Neutropenia 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

5 

Neutropenia (absolute neutrophil count [ANC] < 1.5 x 109/l) has been observed commonly with another 
medicinal product that inhibits IL-1 used in a patient population (rheumatoid arthritis) other than CAPS. 
Neutropenia was observed commonly in patients with rheumatoid arthritis (not an approved use) who 
were administered Rilonacept Regeneron subcutaneously in clinical studies.  None of these patients had 
serious infections associated with the neutropenia. Although neutropenia was observed uncommonly in 
CAPS patients, the numbers studied are small. Treatment with Rilonacept Regeneron should not be 
initiated in patients with neutropenia. It is recommended that neutrophil counts be assessed prior to 
initiating treatment, after 1 to 2 months, and periodically thereafter while receiving Rilonacept Regeneron. 
If a patient becomes neutropenic the ANC should be monitored closely and treatment discontinuation 
should be considered. 
 
Malignancies 
The impact of treatment with Rilonacept Regeneron on the development of malignancies is not known. 
However, treatment with immunosuppressants, including Rilonacept Regeneron, may result in an increase 
in the risk of malignancies.   
 
Vaccines 
Live vaccines should not be given concurrently with Rilonacept Regeneron (see section 4.5). Prior to 
initiation of Rilonacept Regeneron therapy, adult and paediatric patients should receive all recommended 
vaccinations, as appropriate, including pneumococcal vaccine and inactivated influenza vaccine. 
 
Lipid profile changes 
Patients should be monitored for changes in their lipid profiles and provided with medical treatment if 
warranted (see section 4.8). 
 
Mutation in NLRP3 gene 
All cases in the clinical trials had a confirmed mutation in the NLRP3 gene. The efficacy was not 
evaluated in patients without a confirmed NLRP3 gene mutation. 
 
4.5 Interaction with other medicinal products and other forms of interaction 
 
No interaction studies have been performed. 
 
The concomitant administration of Rilonacept Regeneron with any TNF inhibitor is not recommended (see 
section 4.4), because an increased incidence of serious infections has been associated with administration 
of another IL-1 blocker in combination with TNF inhibitors. 
 
The concomitant administration of Rilonacept Regeneron with other IL-1 inhibitors has not been studied 
and is therefore not recommended.  
 
The formation of CYP450 enzymes is suppressed by increased levels of cytokines during chronic 
inflammation. Thus it is expected that for a molecule that binds to IL-1, such as rilonacept, the formation 
of CYP450 enzymes could be normalized. This is clinically relevant for CYP450 substrates with a narrow 
therapeutic index, where the dose is individually adjusted (e.g. warfarin). Upon initiation of Rilonacept 
Regeneron, in patients being treated with these types of medicinal products, therapeutic monitoring of the 
effect or plasma levels should be performed and the individual dose of the medicinal product may need to 
be adjusted as needed.   
 
No data are available on either the effects of live vaccination or the secondary transmission of infection by 
live vaccines in patients receiving Rilonacept Regeneron. Therefore, live vaccines should not be given 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

6 

concurrently with Rilonacept Regeneron, unless the benefits clearly outweigh the risks. Should 
vaccination with live vaccines be indicated after initiation of Rilonacept Regeneron treatment, the 
recommendation is to wait for at least 6 weeks after the last Rilonacept Regeneron injection and before the 
next one (see section 4.4). 
 
4.6 Fertility, pregnancy and lactation 
 
Pregnancy 
There are no adequate data from use of rilonacept in pregnant women. Reproductive toxicity studies have 
been conducted in animals and have shown no effects on fertility or foetal morphology; however a study 
in pregnant monkeys showed reduced levels of oestrogen (see section 5.3). The risk for the foetus/mother 
is unknown. Women should use effective contraceptives during treatment with Rilonacept Regeneron and 
for up to 6 weeks after the last dose. Women who are pregnant or who desire to become pregnant should 
therefore only be treated after a thorough benefit-risk evaluation. 
 
Breast-feeding 
It is unknown whether rilonacept is excreted in human or animal breast milk. A decision on whether to 
continue/discontinue breast-feeding or to continue/discontinue therapy with Rilonacept Regeneron should 
be made taking into account the benefit of breast-feeding to the child and the benefit of Rilonacept 
Regeneron therapy to the woman. 
 
4.7 Effects on ability to drive and use machines 
 
The ability to drive and operate machines may be impaired by some symptoms associated with CAPS. 
Patients who experience vertigo during Rilonacept Regeneron treatment should wait for this to resolve 
completely before driving or operating machines. 
 
4.8 Undesirable effects 
 
The majority of the related adverse events in the clinical trials were classified as injection site reactions, 
experienced by approximately 50% of the patients in the Phase 3 study.  Reported ISRs were generally 
mild to moderate in severity.  No patients withdrew from the study due to ISRs. 
 
ADRs to Rilonacept Regeneron reported during  the Phase 2/3 program in a total of 109 patients, some 
treated for longer than 2 years, are listed below using the following categories of frequency: very common 
(≥1/10); common (≥ 1/100 to <1/10), uncommon (≥1/1000 to <1/100).  
 
Due to the small patient population, an ADR reported in 2 or more patients is classified as 
“common.” 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

7 

Table 2: Adverse reactions with Rilonacept Regeneron in CAPS patients 

MedDRA 
System Organ Class  

Adverse reaction Frequency 

General disorders and 
administration site conditions 
 

Injection site reactions, 
including erythema, bruising, 
pruritus, swelling, 
inflammation, pain, dermatitis, 
oedema, urticaria, vesicles  

very common 
 

Fatigue common 
Infections and infestations Upper respiratory tract 

infection; sinusitis 
very common 
 

Bronchitis; gastroenteritis; 
viral infections; skin, eye and 
ear infections; pneumonia 

common 

Bacterial meningitis uncommon 
Investigations Eosinophil count increased common 
Nervous system disorders Headache very common 

Dizziness common 
Vascular disorders Hypertension, flushing common 
Ear and labyrinth disorders Vertigo common 
Eye disorders Iritis uncommon 
Psychiatric disorders Anxiety, insomnia common 
Immune system disorders Hypersensitivity common 
 
 
Infections and infestations 
During Part A of the pivotal study (see section 5.1), the incidence of patients reporting infections and 
considered by the investigator as related to treatment was greater with Rilonacept Regeneron (9%) than 
with placebo (0%). In Part B, randomised withdrawal, the incidence of infections were similar in the 
Rilonacept Regeneron (0%) and the placebo patients (4%). Part A of the trial was initiated in the winter 
months, while Part B was predominantly performed in the summer months. 
 
In placebo-controlled studies across a variety of patient populations encompassing 336 patients treated 
with rilonacept and 165 treated with placebo, the incidence of infections was 6.8% and 3% (0.44 per 
patient-exposure year and 0.19 per patient-exposure year), respectively, for rilonacept and placebo. 
 
Serious infections 
One patient in an open-label study of CAPS died after developing sinusitis and bacterial (Streptococcus 
pneumoniae) meningitis.  
 
In a study in patients with adult Still’s disease, one patient developed an infection in his elbow with 
Mycobacterium intracellulare after an intraarticular glucocorticoid injection and subsequent local 
exposure to a suspected source of mycobacteria. In a study in patients with polymyalgia rheumatica, one 
patient developed bronchitis and sinusitis, which resulted in hospitalization.  
 
Blood and lymphatic system disorder 
During the initial placebo-controlled portion of the pivotal trial, mean values increased for haemoglobin 
and decreased for neutrophils and platelets in the patients treated with Rilonacept Regeneron. These 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

8 

changes were not deemed as clinically significant and were potentially due to a decrease in the chronic 
inflammatory state present in CAPS with an attendant decrease in acute-phase response. 
 
General disorders and administration site conditions 
In patients with CAPS, the most common and consistently reported adverse event associated with 
treatment was injection-site reaction (ISR). The ISRs included erythema, swelling, pruritus, and bruising. 
Most ISRs lasted for one to two days. In studies of patients with CAPS, no ISRs were assessed as severe, 
and no patient discontinued study participation due to an ISR. 
 
Immunogenicity 
Antibodies directed against the receptor domains of rilonacept were detected by an ELISA assay in 
patients with CAPS after treatment with Rilonacept Regeneron in clinical studies. Nineteen of 55 patients 
(35%) who had received Rilonacept Regeneron for at least 6 weeks tested positive for treatment-emergent 
binding antibodies on at least one occasion.  Of the 19 patients, 7 tested positive at the last assessment 
(Week 18 or 24 of the open-label extension period), and 5 patients tested positive for neutralising 
antibodies on at least one occasion.  There was no correlation of antibody activity and either clinical 
efficacy or safety. 
 
The data reflect the percentage of patients whose test results were positive for antibodies to rilonacept in 
specific assays, and are highly dependent on the sensitivity and specificity of the assays. The observed 
incidence of antibody positivity in an assay may be influenced by several factors including assay 
sensitivity and specificity, sample handling, concomitant medicinal products, and underlying disease. For 
these reasons, comparison of the incidence of antibodies to rilonacept with the incidence of antibodies to 
other products may be misleading. 
 
Changes in lipid parameters 
Cholesterol and lipid levels may be reduced in patients with chronic inflammation. Patients with CAPS 
treated with Rilonacept Regeneron experienced mean increases from baseline for total cholesterol, HDL 
cholesterol, LDL cholesterol, and triglycerides of 19 mg/dl, 2 mg/dl, 10 mg/dl, and 57 mg/dl respectively 
after 6 weeks of open-label therapy. Physicians should monitor the lipid profiles of their patients (for 
example after 2-3 months) and consider lipid-lowering therapies as needed based upon cardiovascular risk 
factors and current guidelines. 
 
4.9 Overdose 
 
No case of overdose has been reported. The maximum amount of product that can be safely administered 
has not been determined. 
 
Intravenous administration of Rilonacept Regeneron at doses of up to 2000 mg monthly in another patient 
population for up to six months was generally well-tolerated. One patient in a study of osteoarthritis 
developed transient neutropenia (absolute neutrophil count < 1 x 109/l) after receiving a very large dose 
(2000 mg). Maximum weekly doses of up to 320 mg have been administered subcutaneously for up to 
approximately 2 years or more in a small number of patients with CAPS and up to 6 months in patients 
with RA in clinical studies without evidence of dose-limiting toxicities.  
 
In case of overdose, it is recommended that the patient be monitored for any signs or symptoms of adverse 
reactions, and appropriate symptomatic treatment instituted immediately. 
 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

9 

5. PHARMACOLOGICAL PROPERTIES 
 
5.1  Pharmacodynamic properties 
 
Pharmacotherapeutic group: Interleukin inhibitors, ATC code: L04AC04. 
 
This medicinal product has been authorised under “Exceptional Circumstances”. This means that due to 
the rarity of the disease it has not been possible to obtain complete information on this medicinal product. 
The EMA will review any new information, which may become available every year, and this SPC will be 
updated as necessary.  
 
Mechanism of action 
Rilonacept is a dimeric fusion protein consisting of the ligand-binding domains of the extracellular 
portions of the human type I interleukin-1 receptor (IL-1RI) and IL-1 receptor accessory protein 
(IL-1RAcP) linked in-line to the Fc portion of human IgG1. Rilonacept binds to and blocks the activity of 
the cytokine IL-1 and binds both IL-1β and IL-1α, which are the primary pro-inflammatory cytokines 
implicated in many inflammatory diseases. Rilonacept also binds the endogenous IL-1 receptor antagonist 
(IL-1ra) but with a lower affinity than IL-1β or IL-1α. 
 
Pharmacodynamic effects 
In clinical studies, CAPS patients who have uncontrolled over-production of IL-1β show a rapid response 
to therapy with rilonacept, i.e. laboratory parameters such as  C-reactive protein (CRP) and serum 
amyloid A (SAA) levels, leukocytosis, and high platelet count rapidly returned to normal. 
 
Clinical efficacy and safety  
The safety and efficacy of rilonacept for the treatment of CAPS, including patients with FCAS, also 
known as familial cold urticaria syndrome (FCUS), and MWS was demonstrated in a randomised, 
double-blind, placebo-controlled study with two parts (A and B) conducted sequentially in the same 
patients. The efficacy portion of the study included 47 patients, 44 of whom had a diagnosis of FCAS and 
3 with a diagnosis of MWS.  Twelve additional patients enrolled during the open label extension in which 
efficacy data were collected, 8 adults with a diagnosis of FCAS and 4 adolescents (13-16 years old), 3 
with FCAS and 1 with FCAS/MWS overlap. Four additional adolescents (12-17 years) all with a diagnosis 
of FCAS subsequently enrolled in the open label extension where efficacy assessments were not collected. 
The efficacy was not evaluated in patients without a confirmed NLRP3/CIAS1 gene mutation. 
 
Part A was a 6-week, randomised, double-blind, placebo-controlled period to evaluate rilonacept at a dose 
of 160 mg weekly after an initial loading dose of 320 mg. Immediately after Part A patients entered Part B 
which consisted of a 9-week, patient-blind period during which all patients received rilonacept 160 mg 
weekly, followed by a 9-week, double-blind, randomised withdrawal period in which patients were 
randomly assigned to either remain on rilonacept 160 mg weekly or to receive placebo. Patients were then 
given the option to enroll in a 24-week, open-label treatment extension phase during which all patients 
were treated with rilonacept 160 mg weekly. 
 
Using a daily diary questionnaire, patients rated the following five signs and symptoms of CAPS: joint 
pain, rash, feeling of fever/chills, eye redness/pain, and fatigue, each on a scale of 0 (none, no severity) to 
10 (very severe). The study evaluated the mean symptom score using the change from baseline to the end 
of treatment.  
 
The changes in mean symptom scores for the randomised parallel-group period (Part A) and the 
randomised withdrawal period (Part B) of the study are shown in Table 3. Patients treated with rilonacept 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

10 

experienced an 84% reduction in the mean symptom score in Part A compared to 13% for placebo-treated 
patients (p< 0.0001). In Part B, mean symptom scores increased more in patients withdrawn to placebo 
compared to patients who remained on rilonacept. 
 
Improvement in key symptom scores was noted within one day of initiation of rilonacept therapy in most 
patients. Patients treated with rilonacept experienced more improvement in each of the five components of 
the composite endpoint than placebo-treated patients.  
 
The mean number of symptomatic “flare” days (defined as a day in which the mean symptom score 
reported on the patient diary was greater than 3) during the 21-day pre-treatment baseline period and the 
on-treatment endpoint period, in Part A, decreased from 8.6 at baseline to 0.1 at endpoint for the group on 
rilonacept, compared to a change from 6.2 to 5.0 for the placebo group (p<0.0001 vs. placebo). 
 
A significantly higher proportion of patients in the rilonacept group compared to the placebo group 
experienced improvement from baseline in the composite score by at least 30% (96% vs. 29% of patients), 
by at least 50% (87% vs. 8%) and by at least 75% (70% vs. 0%) (p<0.0001).   
 
In Part A and Part B, physician’s and patient’s global assessment of disease activity and patients’ 
assessment of the degree of limitation of their daily activities due to their disease were significantly 
improved for patients treated with rilonacept compared with those on placebo.  
 
Mean levels of C reactive protein (CRP) were significantly decreased versus baseline for the rilonacept-
treated patients, while there was no change for those on placebo. Rilonacept also led to a significant 
decrease in serum amyloid A (SAA) versus baseline to levels within the normal range.  
 
During the open-label extension, reductions in mean symptom scores, serum CRP, and serum SAA levels 
were maintained for up to one year. 
 
Table 3:  Mean Symptom Scores in Adults (age 18 and older) 

Part A Placebo (n=24) 
Rilonacept  
(n=23) Part B 

Placebo 
(n=23) 

Rilonacept  
(n=22) 

Pre-treatment 
Baseline Period 
(Weeks -3 to 0) 

2.4 3.1 
Active Rilonacept 
Baseline Period 
(Weeks 13 to 15) 

0.2 0.3 

Endpoint Period 
(Weeks 4 to 6) 2.1 0.5 

Endpoint Period 
(Weeks 22 to 24) 1.2 0.4 

Mean Change 
from Baseline to 
Endpoint 

-0.3 -2.6* Mean Change from Baseline to Endpoint 0.9 0.1** 

p-value for within 
group comparison 
of change from 
Baseline 

NS  p< 0.0001 

p-value for within 
group comparison of 
change from 
Baseline 

p< 0.0001 NS 

*p< 0.0001, comparison of rilonacept vs. placebo 
**p< 0.001, comparison of rilonacept vs. placebo,  
NS = not significant 
 
An assessment of efficacy with respect to age group and diagnosis was obtained by comparing KSS at the 
end of the 24 week open label extension with KSS at baseline using time averaged daily mean scores.  The 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

11 

results for the adults who entered the study in Part A are provided separately from the results of the adults 
who entered directly into the open label extension; the results for the four adolescents who entered directly 
into the open label extension are provided individually. 
 
Table 4: Key symptom scores by age and diagnosis following 24-week open label extension 

Group Age group 
(range) 

Diagnosis Baseline 
Mean KSS 

Week 24 
Mean KSS 

Reduction 
from Baseline 

    
Adults who entered 
in Part A 

18 - <65 
(24, 63) 

FCAS 
n=31 

2.9 0.7 75.9% 

≥ 65 
(67, 78) 

FCAS 
n=10 

2.4 0.4 77.3% 

18 - <65 
(22, 45) 

MWS 
n=3 

3.3 0.2 90.5% 

    
Adults who entered 
in OLE 

18 - <65 
(18, 56) 

FCAS 
n=8 

2.3 0.2 93.0% 

    
Adolescents who 
entered in OLE 

13 FCAS 2.4 0.4 85.6% 
15 FCAS 0.3 0.0 100% 
16 FCAS 2.8 0.0 100% 
13 FCAS/MWS 0.7 0.0 95.7% 

 
5.2 Pharmacokinetic properties 
 
Bioavailability of rilonacept after a subcutaneous injection is estimated to be approximately 50%. 
 
The average trough levels of rilonacept were approximately 24 µg/ml at steady state following weekly 
subcutaneous doses of 160 mg for up to 48 weeks in patients with CAPS. The steady state appeared to be 
reached by 6 weeks. 
 
Table 5: Rilonacept steady-state pharmacokinetic properties1 
Parameter Value2 

Cmax (mg/l) 
 
31.5 

 
AUC (day mg/l) 

 
198 

 
CL /F (l/day) 

 
0.808 

 
T1/2 terminal (day) 

 
7.72 
 

1 Based on population PK modelling 
2 Derived values are presented.    
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

12 

Special populations  
No pharmacokinetic data are available in patients with hepatic impairment. As with other large proteins 
elimination of rilonacept is expected to be via proteolytic catabolism and target mediated clearance. 
Consequently, impaired liver function is not expected to affect the pharmacokinetics of rilonacept in a 
clinically significant way. 
 
Results of a single-dose study in patients with end-stage renal disease (ESRD) indicate that the rate of 
elimination of rilonacept was not decreased. Renal elimination of rilonacept is therefore considered to be a 
minor pathway for clearance. No dose adjustment is needed in patients with renal impairment. 
 
No study was conducted to evaluate the effect of age, gender, or body weight on rilonacept exposure. 
Based on limited data obtained from the clinical study, steady-state trough concentrations were similar 
between male and female patients. Age (26-78 years old) and body weight (50-120 kg) did not appear to 
have a significant effect on trough rilonacept concentrations. The effect of race could not be assessed 
because only Caucasian patients participated in the clinical studies in CAPS, reflecting the epidemiology 
of the disease.   
 
5.3 Preclinical safety data 
 
Non-clinical data reveal no special hazard for humans based on conventional studies of safety 
pharmacology and repeated-dose toxicity. 
 
Animal studies were conducted to assess reproductive toxicity. In mice, a murine analogue of rilonacept 
had no effect on fertility. A study of embryo-foetal development was conducted with rilonacept in 
monkeys at doses up to approximately 4 times the human dose. Decreases in β-estradiol levels were seen 
in the treated groups, the significance of this finding is unknown. In a prenatal and postnatal reproductive 
toxicology study in which mice were dosed subcutaneously, with a murine analogue of rilonacept at doses 
of 20, 100 or 200 mg/kg three times per week (the highest dose is approximately 6-fold higher than the 
160 mg maintenance dose based on body surface area), there were no treatment-related effects.  
 
Genotoxicity or long term animal studies have not been performed to evaluate the mutagenic or 
carcinogenic potential of rilonacept. 
 
 
6. PHARMACEUTICAL PARTICULARS 
 
6.1 List of excipients 
 
Powder 
Glycine 
Arginine hydrochloride 
Histidine 
Histidine hydrochloride monohydrate 
Polyethylene glycol 3350 
Sucrose 
 
Solvent 
Water for injections  
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

13 

6.2 Incompatibilities 
 
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal 
products. 
 
6.3 Shelf life 
 
Vial 
2 years. 
 
Diluted solution 
From a microbiological safety point of view, the product should be used as soon as possible but within 3 
hours of reconstitution, because it does not contain a preservative. If not used immediately, in-use storage 
times and conditions prior to use are the responsibility of the user and should not be longer than 24 hours 
at 2 to 8°C.   
 
6.4 Special precautions for storage 
 
Store in a refrigerator. Do not freeze. 
Keep the vials in the outer carton in order to protect from light.  
 
For storage conditions after reconstitution of the medicinal product, see section 6.3. 
 
6.5 Nature and contents of container 
 
Powder vial 
20 ml clear type I glass vial with  rubber stopper and lacquered flip-off aluminium seal containing 220 mg 
rilonacept.  
 
Solvent vial 
LDPE vials containing 5 ml water for injections 
Each pack contains:  
4 vials of powder for solution for injection 
4 vials of solvent 
8 disposable 3 ml syringes 
8 disposable 27 gauge, ½-inch needles 
 
6.6 Special precautions for disposal and other handling 
 
Instructions for reconstitution 
 
Using aseptic technique, Rilonacept Regeneron powder should be reconstituted with 2.3 ml of solvent 
(water for injections) prior to administration.  
 
The 2.3 ml of solvent should be withdrawn from the solvent vial attached directly to a 3 ml syringe and 
then injected into the powder vial for reconstitution using the 27 gauge, ½-inch needle (to obtain a final 
reconstitution volume of 2.75 ml). The needle and syringe used for reconstitution with solvent should then 
be discarded and should not be used for subcutaneous injections. After the addition of solvent, the vial 
contents should be reconstituted by shaking the vial for approximately one minute and then allowing it to 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

14 

sit for one minute. The resulting 80 mg/ml solution is sufficient to allow a withdrawable volume of up to 2 
ml for subcutaneous administration.  
 
The reconstituted solution is viscous, clear and colourless to pale yellow. Prior to injection, the 
reconstituted solution should be carefully inspected for any discolouration or particulate matter. If there is 
discolouration or particulate matter in the solution, the product must not be used.  
 
Instructions for administration 
 
Using aseptic technique, the recommended dose volume, up to 2 ml (160 mg) of the solution, should be 
withdrawn with a new 27 gauge, ½-inch injection needle attached to a new 3 ml syringe for subcutaneous 
injection.  
 
Sites for subcutaneous injection, such as the abdomen, thigh, or upper arm, should be rotated. Injections 
should never be made at sites that are bruised, red, tender, or hard.  
 
The initial administration of Rilonacept Regeneron by a patient or caregiver should be under the guidance 
of a trained healthcare professional. For subsequent self-administration by patients, appropriate instruction 
in proper injection technique should be provided and ability to apply that technique ascertained.  
 
Disposal 
 
Each vial should be used for a single dose only. The vial should be discarded after withdrawal of the 
solution. 
 
Patients or their caregivers should be instructed on the appropriate procedure for disposal of the vials, 
needles, and syringes. 
 
Any unused medicinal product or waste material should be disposed of in accordance with local 
requirements. 
 
 
7. MARKETING AUTHORISATION HOLDER 
 
Regeneron UK Limited 
40 Bank Street  
E14 5DS London 
United Kingdom 
 
 
8. MARKETING AUTHORISATION NUMBER(S)  
 
EU/1/09/582/001 
 
 
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION 
 
Date of first authorisation: 23 October 2009 
Date of latest renewal:  
 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

15 

10. DATE OF REVISION OF THE TEXT 
 
 
Detailed information on this medicinal product is available on the website of the European Medicines 
Agency http://www.ema.europa.eu. 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

16 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

 ANNEX II 
 

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE 
SUBSTANCE(S) AND  MANUFACTURER(S) RESPONSIBLE 
FOR BATCH RELEASE 

 
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY 

AND USE  
 
C. OTHER CONDITIONS AND REQUIREMENTS OF THE 

MARKETING AUTHORISATION 
 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

17 

A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND 
MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE 

 
Name and address of the manufacturer of the biological active substance 
 
Regeneron Pharmaceuticals, Inc. 
81 Columbia Turnpike, Rensselaer,  
New York 12144 
USA 
 
Name and address of the manufacturer responsible for batch release 
 
Brecon Pharmaceuticals Ltd. 
Pharos House 
Wye Valley Business Park  
Brecon Road, Hay-on-Wye 
Hereford HR3 5PG 
United Kingdom 
 
 
B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE 
 
 
Medicinal product subject to restricted medical prescription (see Annex I: Summary of Product 
Characteristics, section 4.2). 
 
• Official batch release 
 
In accordance with Article 114 of Directive 2001/83/EC, the official batch release will be undertaken by a 
state laboratory or a laboratory designated for that purpose. 
 
 
C.  OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING 

AUTHORISATION 
 
The Marketing Authorisation Holder (MAH) shall ensure that, prior to launch, all physicians who are 
expected to prescribe/use Rilonacept Regeneron are provided with a physician information pack 
containing the following: 

• The Summary of Product Characteristics 
• Physician information 
• Patient Alert Card 

 
The physician information should contain the following key messages: 

• The risk of serious infections, including opportunistic bacterial, viral and fungal infections in 
patients treated with Rilonacept Regeneron; 

• The risk of acute injection-related reactions; 
• The need to instruct patients on proper techniques for self-administration when the patient is 

willing and capable to do so, and guidance for Health Care Professionals on how to report 
administration errors; 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

18 

• The identified or potential risk of immunogenicity that might lead to immune-mediated symptoms; 
• The need for Health Care Professionals to perform an annual clinical assessment of patients 

regarding a potential increased risk for the development of malignancies; 
• The need to measure neutrophil counts prior to initiating treatment, after 1 to 2 months and 

periodically thereafter while receiving Rilonacept Regeneron as treatment with Rilonacept 
Regeneron should not be initiated in patients with neutropenia; 

• The need to monitor patients for changes in their lipid profiles; 
• The unknown safety of Rilonacept Regeneron in pregnant and lactating women, thus the need for 

physicians to discuss this risk with patients if they become or plan to become pregnant; 
• The proper patient management as regards the interaction with vaccination; 
• The possibility to include patients in the registry study to facilitate the collection of long term 

efficacy and safety data; 
• The role and use of patient alert card. 

 
Pharmacovigilance system 
The MAH must ensure that the system of pharmacovigilance presented in Module 1.8.1 of the Marketing 
Authorisation, is in place and functioning before and whilst the medicinal product is on the market. 
 
Risk Management Plan (RMP) 
The MAH shall perform the pharmacovigilance activities detailed in the Pharmacovigilance Plan, as 
agreed in the RMP presented in Module 1.8.2 of the Marketing Authorisation and any subsequent updates 
of the RMP agreed by the Committee for Medicinal Products for Human Use (CHMP). 
 
As per the CHMP Guideline on Risk Management Systems for medicinal products for human use, the 
updated RMP should be submitted at the same time as the next Periodic Safety Update Report (PSUR). 
 
In addition, an updated RMP should be submitted 

• When new information is received that may impact on the current Safety Specification, 
Pharmacovigilance Plan or risk minimisation activities 

• Within 60 days of an important (pharmacovigilance or risk minimisation) milestone being reached 
• At the request of the European Medicines Agency. 

 
PSURs 
The PSUR cycle for the medicinal product should follow a half-yearly cycle until otherwise agreed by the 
CHMP. 
 
• CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE 

USE OF THE MEDICINAL PRODUCT 
 
Not applicable. 
 
• OBLIGATION TO CONDUCT POST-AUTHORISATION MEASURES 
 
The MAH shall complete, within the stated timeframe, the following measures: 
 
Description Due date 
The MAH shall submit an updated risk management plan (RMP) that adequately 
describes the additional pharmacovigilance activity of performing an embryo-foetal 
developmental toxicity study in cynomolgus monkeys to further investigate the 

Within a month 
following the 
notifications of 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

19 

potential risk of foetal defects. 

 

the Commission 
Decision 

 
 
• SPECIFIC OBLIGATION TO COMPLETE POST-AUTHORISATION MEASURES FOR 

THE MARKETING AUTHORISATION UNDER EXCEPTIONAL CIRCUMSTANCES 
 
This being an approval under exceptional circumstances and pursuant to Article 14(8) of Regulation (EC) 
No 726/2004, the MAH shall conduct, within the stated timeframe, the following measures: 
 
Description Due date 
The MAH is requested to provide regular safety and efficacy data from the Global 
Registry for both adults and children.  The fact that a limited number of paediatric 
patients were included in the clinical studies combined with the lack of data on the 
effect of long term IL-1ß suppression is a concern in view of the orphan nature of the 
condition. The continued collection of data should be maintained from the registry on 
safety and efficacy in children; particularly risk of infection and possible impairment 
of immune reactions such as response to vaccinations and growth. In addition the 
MAH is requested to assess cases for which there is loss of efficacy to determine 
whether this is due to changes over time in PK/PD or antibody development. The 
MAH shall provide updates on the recruitment rates and any intermediary results with 
the PSURs. The patients should be included in the Registry until both following 
conditions are met: 5 years recruitment period and 200 patients included. 

With PSUR 

Further PK steady state exposure data (AUC, Cmax, Cmin during steady state) especially 
for paediatric subjects is required. The MAH is requested to perform a PK study in 
children. 

30 September 
2012 

 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

20 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

ANNEX III 
 

LABELLING AND PACKAGE LEAFLET 
 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

21 

 
 

A. LABELLING 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

22 

 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING 
 
OUTER CARTON  
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
Rilonacept Regeneron 80 mg/ml powder and solvent for solution for injection 
rilonacept 
 
2. STATEMENT OF ACTIVE SUBSTANCE(S) 
 
Each vial of powder contains 220 mg rilonacept. After reconstitution, each ml of solution contains 80 mg 
rilonacept. 
 
3. LIST OF EXCIPIENTS 
 
Also contains: glycine, arginine hydrochloride, histidine, histidine hydrochloride monohydrate 
polyethylene glycol 3350, sucrose, and water for injections. 
 
4. PHARMACEUTICAL FORM AND CONTENTS 
 
Powder and solvent for solution for injection. 
 
Contains: 
4 vials of powder containing 220 mg rilonacept 
4 vials of 5 ml solvent 
8 disposable 3 ml syringes 
8 disposable 27-gauge, 1/2-inch needles 
 
5. METHOD AND ROUTE(S) OF ADMINISTRATION 
 
Read the package leaflet before use. 
Subcutaneous use. 
 
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 
 
Keep out of the sight and reach of children. 
 
7. OTHER SPECIAL WARNING(S), IF NECESSARY 
 
 
8. EXPIRY DATE 
 
EXP  
 
9. SPECIAL STORAGE CONDITIONS
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

23 

Store in a refrigerator. Do not freeze. 
Keep the vials in the outer carton in order to protect from light. 
 
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE 

 
Any unused product or waste material should be disposed of in accordance with local requirements. 
 
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
 
Regeneron UK Limited 
40 Bank Street 
E14 5DS London 
United Kingdom 
 
12. MARKETING AUTHORISATION NUMBER(S) 
 
EU/1/09/582/001 
 
13. BATCH NUMBER 
 
Lot  
 
14. GENERAL CLASSIFICATION FOR SUPPLY 
 
Medicinal product subject to medical prescription. 
 
15. INSTRUCTIONS ON USE 
 
 
16. INFORMATION IN BRAILLE 
 
Justification for not including Braille accepted. 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

24 

PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGING 
 
POWDER VIAL LABEL 
 
 
1. NAME OF THE MEDICINAL PRODUCT 
 
Rilonacept Regeneron 80 mg/ml powder for solution for injection 
rilonacept 
 
2. STATEMENT OF ACTIVE SUBSTANCE(S) 
 
Each vial contains 220 mg of rilonacept. When reconstituted, each ml solution contains 80 mg of 
rilonacept. 
 
3. LIST OF EXCIPIENTS 
 
Also contains: glycine, arginine hydrochloride, histidine, histidine hydrochloride monohydrate 
polyethylene glycol 3350, sucrose 
 
4. PHARMACEUTICAL FORM AND CONTENTS 
 
Powder for solution for injection. 
220 mg rilonacept 
 
5. METHOD AND ROUTE(S) OF ADMINISTRATION 
 
Read the package leaflet before use. 
Subcutaneous use. 
 
6. SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT 

OF THE SIGHT AND REACH OF CHILDREN 
 
Keep out of the sight and reach of children. 
 
7. OTHER SPECIAL WARNING(S), IF NECESSARY 
 
 
8. EXPIRY DATE 
 
EXP  
 
9. SPECIAL STORAGE CONDITIONS
 
Store in a refrigerator. Do not freeze. 
Keep the vial in the outer carton in order to protect from light. 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

25 

 
10. SPECIAL PRECAUTIONS FOR DISPOSAL OF UNUSED MEDICINAL PRODUCTS 

OR WASTE MATERIALS DERIVED FROM SUCH MEDICINAL PRODUCTS, IF 
APPROPRIATE 

 
 
11. NAME AND ADDRESS OF THE MARKETING AUTHORISATION HOLDER 
 
Regeneron UK Limited 
40 Bank Street 
E14 5DS London 
United Kingdom 
 
12. MARKETING AUTHORISATION NUMBER(S) 
 
EU/1/09/582/001 
 
13. BATCH NUMBER 
 
Lot 
 
14. GENERAL CLASSIFICATION FOR SUPPLY 
 
Medicinal product subject to medical prescription. 
 
15. INSTRUCTIONS ON USE 
 
 
16. INFORMATION IN BRAILLE 
 
Justification for not including Braille accepted. 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

26 

 
 
MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS 
 
SOLVENT LABEL 
 
 
1. NAME OF THE MEDICINAL PRODUCT  AND ROUTE(S) OF ADMINISTRATION 
 
Solvent for Rilonacept Regeneron  
 
2. METHOD OF ADMINISTRATION 
 
Read the package leaflet before use. 
 
3. EXPIRY DATE 
 
EXP 
 
4. BATCH NUMBER 
 
Lot  
 
5. CONTENTS BY WEIGHT, BY VOLUMEN OR BY UNIT 
 
5 ml 
 
6. OTHER 
 
Water for injections. 
 
 
 
 
 
 
 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

27 

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

B. PACKAGE LEAFLET 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

28 

Package leaflet: Information for the user 
 

Rilonacept Regeneron 80 mg/ml powder and solvent for solution for injection 
rilonacept 

 
 
Read all of this leaflet carefully before you start using this medicine because it contains important 
information for you. 
- Keep this leaflet. You may need to read it again. 
- If you have further questions, ask your doctor or pharmacist. 
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if 

their signs of illness are the same as yours. 
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 

not listed in this leaflet. 
 
 
What is in this leaflet: 
 
1.  What Rilonacept Regeneron is and what it is used for 
2.  What you need to know before you use Rilonacept Regeneron 
3.  How to use Rilonacept Regeneron 
4.  Possible side effects 
5.  How to store Rilonacept Regeneron 
6.  Contents of the pack and other information 
 
 
1. What Rilonacept Regeneron is and what it is used for 
 
Rilonacept Regeneron is used to treat adults and adolescents aged 12 years and older with severe 
symptoms of Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS).  
 
Rilonacept Regeneron belongs to a group of medicines called interleukin inhibitors. Rilonacept Regeneron 
blocks the activity of substances including interleukin-1 beta (IL-1 beta). In patients with CAPS, the body 
produces excessive amounts of IL-1 beta. This may lead to symptoms such as fever, headache, fatigue, 
skin rash, or painful joints and muscles. By blocking the activity of IL-1 beta, Rilonacept Regeneron leads 
to an improvement in these symptoms. 
 
If you have any questions about how Rilonacept Regeneron works or why this medicine has been 
prescribed for you, ask your doctor. 
 
2. What you need to know before you use Rilonacept Regeneron 
 
Do not use Rilonacept Regeneron: 
• if you are allergic to rilonacept or any of the other ingredients of this medicine (listed in section 6). 
• if you have an active, severe infection. 
 
Warnings and precautions 
 
Talk to your doctor before using Rilonacept Regeneron. 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

29 

 
You should tell your doctor if you have: 
• an infection; 
• tuberculosis or you have been in close contact with someone who has had tuberculosis; 
• a history of infections that keep coming back; 
• been scheduled to receive any vaccines. 
 
Children and adolescents 
 
Rilonacept Regeneron is not recommended for children younger than 12 years of age. 
 
Other medicines and Rilonacept Regeneron 
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. 
 
In particular, you should tell your doctor if you are using any of the below medicines: 
• Other medicines that block interleukin-1, such as anakinra or canakinumab. 
• Medicines called Tumour Necrosis Factor (TNF) inhibitors (such as etanercept, adalimumab, or 

infliximab) predominantly used in rheumatoid and autoimmune disease. 
• Any other medicines for chronic disorders, as Rilonacept Regeneron can affect how the liver processes 

some medicines, such as warfarin (a blood thinner). Your doctor may need to perform some tests and 
adjust the dose of such medicines. 

 
Pregnancy and breast-feeding 
 
Rilonacept Regeneron has not been tested in pregnant women and should not be used during pregnancy 
unless clearly necessary. You should not become pregnant and must use birth control while using 
Rilonacept Regeneron and for at least six weeks after your last dose. If you are pregnant, think you may be 
pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.  
 
The safety of Rilonacept Regeneron in breast-feeding women is unknown. If you are breast-feeding you 
should ask your doctor for advice before using Rilonacept Regeneron.  
 
Driving and using machines 
 
Some symptoms associated with CAPS or with Rilonacept Regeneron treatment, such as a spinning 
sensation (known as vertigo), may affect your ability to drive or use machines. If you feel a spinning 
sensation, do not drive or operate any tools or machines until you are feeling normal again. 
 
Ask your doctor, nurse or pharmacist for advice before taking any medicine. 
 
 
3. How to use Rilonacept Regeneron 
 
Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if 
you are not sure. 
 
Rilonacept Regeneron is intended for subcutaneous use. This means that it is injected through a short 
needle into the fatty tissue just under the skin. 
 
How much Rilonacept Regeneron to use 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

30 

Adults (including the elderly) 
• The starting dose is 2 injections of 2 millilitres (ml) solution each, given on the same day at 2 different 

areas of the body. 
• After that, the recommended dose is 1 injection of 2 ml injected once weekly.  
 
Adolescents (aged 12 to 17 years old) 
The dose will depend on the body weight of the patient and will be different for each patient. Your doctor 
will tell you how much medicine to inject. 
• The starting dose is 4.4 milligrams per kilogram of body weight, up to 320 milligrams (mg), given as 

one or two injections.   
• After that, the recommended dose is 2.2 milligrams per kilogram, up to 160 mg, once weekly on the 

same day of the week. 
In both cases your doctor will calculate the corresponding volume to inject. The dose of Rilonacept 
Regeneron may need to be adjusted as the child grows. Talk with your doctor before making any dose 
adjustments. 
 
How to inject Rilonacept Regeneron 
Rilonacept Regeneron is injected under the skin (subcutaneously). The first injection of Rilonacept 
Regeneron should be given under the supervision of a trained healthcare professional. You or your 
caregiver will receive adequate training on how to mix the powder (dissolve to make a solution), prepare 
the dose, and administer the injection.  
 
Please read the section “INSTRUCTIONS FOR USE OF RILONACEPT REGENERON POWDER FOR 
SOLUTION FOR INJECTION” at the end of this leaflet. If you have questions, contact your doctor, 
nurse, or pharmacist.  
 
If you use more Rilonacept Regeneron than you should 
If you accidentally inject more Rilonacept Regeneron than the recommended dose, you should contact 
your doctor right away. 
 
If you forget to use Rilonacept Regeneron  
If you miss a dose of Rilonacept Regeneron and remember within a few days, inject it as soon as you 
remember. The next dose should be injected at the next regularly scheduled time. Do not inject a double 
dose to make up for the forgotten dose. Do not inject Rilonacept Regeneron more frequently than once 
weekly. 
 
 
4. Possible side effects   
 
Like all medicines, this medicine can cause side effects, although not everybody gets them. 
 
You must tell your doctor right away if any of the following serious side effects occur while you are using 
Rilonacept Regeneron: 
 
• Serious infections. Tell your doctor right away if you develop symptoms of an infection while being 
treated with Rilonacept Regeneron, such as: 

- fever lasting longer than 3 days, or any other symptoms possibly related to an infection, such as 
prolonged cough, prolonged headache or localised redness, warmth or swelling of your skin. 

You must stop treatment with Rilonacept Regeneron if you develop a severe infection. 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

31 

• Allergic reactions. If you develop signs of an allergic (hypersensitivity) reaction during treatment with 
Rilonacept Regeneron (such as chest tightness, wheezing, trouble breathing, severe dizziness or light-
headedness, swelling of lips, or rash during or after the injection) then stop taking Rilonacept Regeneron 
and tell your doctor right away. 
 
Very common side effects (affects 1 or more users in 10) 
 • Reactions at injection site (such as redness, swelling, itching, and bruising at the injection site) 
 • Upper respiratory infection 
 • Sinus infection 
 • Headache 
 
Common side effects (affects 1 to up to 10 users in 100) 
 • Viral infection 
 • Bronchitis 
 • Skin, eye, or ear infection 
 • Tiredness (fatigue) 
 • Increased blood pressure 
 • Pneumonia 
 • Stomach/Intestinal infection 
 • Dizziness 
 • Flushing 
 • Allergic reaction 
 • Anxiety 
 • Being unable to sleep (insomnia) 
 
Uncommon side effects (affects 1 to up to 10 users in 1,000) 
 • Meningitis 
 • Inflammation of the eye (iritis) 
 
Changes in your blood cholesterol levels or in your blood counts may also occur. These will be monitored 
by your doctor. 
 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not 
listed in this leaflet. 
 
 
5. How to store Rilonacept Regeneron  

 
Keep this medicine out of the sight and reach of children. 
 
Do not use this medicine after the expiry date which is stated on the carton and vial label after EXP. The 
expiry date refers to the last day of that month. 
 
Store in a refrigerator. Do not freeze. 
 
Keep the vials in the outer carton in order to protect from light. 
 
After preparing the Rilonacept Regeneron solution, it is best if used right away because it does not contain 
a preservative. If necessary, the product may be kept at room temperature, but should be used within 3 
hours of mixing. 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

32 

 
The solution is viscous, clear and colourless to pale yellow. Prior to injection, the solution should be 
carefully inspected for any discolouration or particulate matter. If there is discolouration or particulate 
matter in the solution, the product must not be used.  
 
Do not throw any medicines via wastewater or household waste. Ask your pharmacist how to throw away 
medicines you no longer use. These measures will help protect the environment. 
 
6. Contents of the pack and other information  
 
What Rilonacept Regeneron contains 
 

-  The active substance is rilonacept. Each vial of powder contains 220 mg rilonacept. After 
 reconstitution, each ml of solution contains 80 mg rilonacept. 
 

-  The other ingredients in the powder are glycine, arginine hydrochloride, histidine, histidine 
 hydrochloride monohydrate, polyethylene glycol 3350 and sucrose. The solvent is water for 
 injections. 

 
What Rilonacept Regeneron looks like and contents of the pack 
 

- Rilonacept Regeneron is provided as a powder for solution for injection in a glass vial. The powder 
is white to off-white. 

 
- Solvent is provided in a 5 ml transparent plastic vial  containing 5 ml water for injections. The 

solvent is a colourless liquid. 
 
Each pack contains: 
 
4 vials of powder for solution for injection 
4 vials of solvent 
8 disposable 3-ml syringes  
8 disposable 27-gauge, ½-inch needles 
 
Marketing Authorisation Holder  
 
Regeneron UK Limited 
40 Bank Street 
E14 5DS London 
United Kingdom 
 
Manufacturer 
Brecon Pharmaceuticals Ltd 
Wye Valley Business Park 
Hay-on-Wye 
HR3 5PG Hereford 
United Kingdom 
 
This leaflet was last revised in  
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

33 

This medicine has been given ‘conditional approval’. This means that there is more evidence to come 
about this medicine. 
The European Medicines Agency will review new information on this medicine at least every year and 
this leaflet will be updated as necessary. 
 
Other sources of information 
 
Detailed information on this medicine is available on the European Medicines Agency web site: 
http://www.ema.europa.eu. 
 
This leaflet is available in all EU/EEA languages on the European Medicines Agency website. 
 
 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

34 

INSTRUCTIONS FOR USE OF RILONACEPT REGENERON POWDER FOR SOLUTION FOR 
INJECTION 

 
See also section 3, “How to inject Rilonacept Regeneron.” 
 
Read these instructions all the way through before beginning. 
 
Supplies needed: 
 
The following items are included in each Rilonacept Regeneron dose pack: 
 

• 8 sterile, 3-ml disposable syringes  
• 8 sterile, disposable needles (27-gauge, ½-inch)  
• 4 vials of Rilonacept Regeneron powder  
• 4 vials of sterile water (solvent) 

 
You will also need to obtain these items from your pharmacist, which are not included in the Rilonacept 
Regeneron dose pack: 
 

• Alcohol wipes 
• Gauze pads 
• A puncture-resistant container for disposal of used needles, syringes, and vials  

 
Ask your pharmacist for these supplies. 

 
General guidelines when giving a Rilonacept Regeneron injection: 
 
•  Check the expiration date (month and year) on the Rilonacept Regeneron carton and vial. It is stated 
 on the vial label and carton after “EXP”. Do not use Rilonacept Regeneron after the expiry date. The 
 expiry date refers to the last date of the month. 
•  Do not touch the needles or the rubber stopper on the Rilonacept Regeneron vial with your hands. If 
 you do touch the rubber stopper, clean it with a fresh alcohol wipe. 
• If you touch a needle or the needle touches any surface, throw away the entire syringe into your 
 puncture-resistant container and start over with a new syringe. 
•  Do not reuse needles or syringes.  
• To protect yourself and others from possible needle sticks, it is very important to throw away every 
 syringe, with the needle attached, in the puncture-resistant container right after use. Do not try to 
 recap the needle. 
 
STEP 1: Setting up for an injection  
 
1. Wash your hands thoroughly. 
 
2. Put the following items on a clean flat surface (see Figure 1): 

• 2 sterile, 3-ml disposable syringes 
• one used for adding the sterile water (solvent) to the Rilonacept Regeneron powder 
• one used for injection  

• 2 sterile, disposable needles (27-gauge, ½-inch)  
• one used for adding the sterile water (solvent) to the Rilonacept Regeneron powder 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

35 

• one used for injection  
• 1 vial of Rilonacept Regeneron powder 
• 1 vial of sterile water (solvent) 
• 3 alcohol wipes 
• 1 gauze pad 
• 1 puncture-resistant container for disposal of used needles, syringes and vials  
  

 
 
 
 
 
 
 

 
 
 

 
Figure 1 

 
 
STEP 2: Preparing the vial of Rilonacept Regeneron powder 
 
1. Remove the plastic cap from the Rilonacept Regeneron vial. 
 
2. Clean the top of the Rilonacept Regeneron vial with a fresh, never-used alcohol wipe, wiping in one 

direction around the top.  
 
3. Set the vial aside. 
 
STEP 3: Filling a syringe with sterile water for injection (solvent)  
 
1. Snap off the plastic tab on the top of the vial containing sterile water for injection (solvent). 
 
2. Open the wrapper that contains a 27-gauge needle by pulling apart the tabs. Place the capped needle 

on a clean surface. Open the wrapper that contains a syringe by pulling apart the tabs. 
 
3. Attach the exposed top of the sterile water vial to the top of a syringe by twisting the syringe onto 

the vial of sterile water (solvent) (see Figure 2). 
 
 
 
 
 
 
 
 

 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

36 

 
 
 
 
 
 
 
 
 

 
Figure 2 

 
4. Hold the vial with the sterile water (solvent) in one hand and the syringe in the other hand. 

Carefully turn the vial upside down. While holding the syringe at eye level, slowly pull the syringe 
plunger back to the 2.5-ml line so that the sterile water (solvent) moves from the vial into the 
syringe (see Figure 3). 

 
 
 
 
 
 
 
 
 
 
 
 
 

Figure 3 
 
5. Remove the vial from the syringe. Hold the barrel of the syringe with one hand and twist the 

27-gauge needle onto the tip of the syringe with the other hand until it fits snugly (see Figure 4). 
 

 
 
 
 
 
 
 
 
 
 
 
 

Figure 4 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

37 

6. Turn the syringe so that the needle is facing straight up. Pull the needle cap straight off. Do not twist 
the needle or the cap as you pull it off. Gently tap the syringe until air bubbles rise to the top of the 
syringe (see Figure 5).  

  
 
 
 
 
 
 
 
 
 
 
 
 

Figure 5 
 

7. Point the syringe and needle straight upward. The sterile water should be at the 2.3-ml line (see 
Figure 6). If there is more sterile water in syringe, then push the syringe plunger to force out sterile 
water until the water reaches the 2.3-ml line. 

 
 
 
 
 
 
 
 
 
 
 
 
 

 
 

Figure 6 
 
STEP 4: Dissolving Rilonacept Regeneron powder with the sterile water for injection (solvent) 
 
1. With one hand, hold the Rilonacept Regeneron powder vial on a firm surface. 
 
2. With the other hand, take the syringe with the sterile water (solvent) and slowly insert the needle 

straight down through the centre of the rubber stopper of the Rilonacept Regeneron powder vial. 
Push the syringe plunger down all the way so that the sterile water (solvent) in the syringe flows 
into the vial (see Figure 7).  



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

38 

 
 
 
 
 
 
 

 
 

 
 

 
Figure 7 

 
3. Remove the syringe and needle from the stopper and throw away the syringe attached to the needle 

and sterile water (solvent) vial in the puncture-resistant container. Do not try to put the needle cover 
back on the needle. 

 
4. Hold the vial containing the mixture of powder and sterile water (solvent) sideways (not upright) 

with your thumb and a finger at the top and bottom of the vial, and quickly shake the vial back and 
forth (side-to-side) for about 1 minute. 

 
5. Put the vial back on the table and let the vial sit for about 1 minute.  
 
6. Check if the vial contains any particles or clumps of powder that have not dissolved.  
 
7. If the powder has not completely dissolved, shake the vial quickly back and forth for 30 seconds 

more. Let the vial sit for about 1 minute. 
 
8. Repeat step 7 until the powder is completely dissolved and the solution is clear. 
 
9. The dissolved Rilonacept Regeneron solution should be a thick, clear liquid, colourless to pale 

yellow. Do not use the solution if it is discoloured or cloudy, or if it contains small particles (see 
Figure 8).  

 
NOTE: Contact your pharmacy to report any dissolved Rilonacept Regeneron that is discoloured or 
contains particles. 

 
 
 
 
 
 
 
 
 
 
 

 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

39 

 
Figure 8 

 
10. It is best to move to the next step and inject the medicine immediately after dissolving the 

Rilonacept Regeneron powder in the sterile water (solvent). If necessary, the product may be kept at 
room temperature (20 to 25°C) for no more than 3 hours. Keep Rilonacept Regeneron away from 
light. 

 
STEP 5: Preparing the injection   
 
1. Hold the vial with the solution on a firm surface and wipe the top of the vial with a new alcohol 

wipe. 
 
2. Open a wrapper containing a new, sterile, disposable needle. Open a wrapper containing a new, 

disposable syringe. Attach the needle securely to the syringe without removing the needle cover. 
 
3. Hold the syringe upright at eye level. With the needle cover on, pull back the plunger on the syringe 

to the mark that is equal to the volume of the solution that your doctor has prescribed for you to 
inject, filling the syringe with air (see Figure 9).  

 
 
 

 
 
 
 
 
 
 
 
 
 
 

                    
                    

Figure 9 
 
4. Remove the needle cover and be careful not to touch the needle. Keep the vial on a flat surface and 

slowly insert the needle straight down through the stopper. Push the plunger down and inject all the 
air into the vial (see Figure 10).  



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

40 

 
 
 

  
 
 
 
 
 
 
 
 
 

      
 

 
Figure 10 

 
5. Hold the vial in one hand and the syringe in the other hand and carefully turn the vial upside down 

so that the needle is pointing straight up. Hold the vial at eye level.  
 
6. Keep the tip of the needle in the liquid and slowly pull back on the plunger to the mark on the 

syringe that matches the amount of medicine prescribed by your doctor (see Figure 11). 
 
 
 
 
 
 
 
 
 
 
 
 
 

 
Figure 11 

 
7. Tap the syringe until the air bubbles rise to the top of the syringe. Then slowly and gently, push in 

the plunger so that all of the air is pushed through the needle.  
 
8. Check to make sure that you have the amount of medicine prescribed by your doctor in the syringe. 
 
9. Throw away the vial in the puncture-resistant container even if there is some medicine left in the 

vial. Do not use any vial of Rilonacept Regeneron more than one time. 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

41 

10. Hold the syringe and needle in your hand ready for injecting. Do not touch the needle with your 
hands or allow it to come into contact with any surfaces. Proceed with the injection as described in 
Step 6 below. 

 
STEP 6: Giving the injection 
 
1. Rilonacept Regeneron is injected into the tissue directly below the layers of skin. It is not meant to 

go into any muscle, vein, or artery.  
 

Where to inject 
 
Inject in a different place each time in order to keep your skin healthy.  

 
Changing injection sites helps to prevent irritation and allows the medicine to be better absorbed. 
Ask your doctor any questions that you have about rotating injection sites.   

 
• Do not inject into skin that is tender, red, or hard. If an area is tender or feels hardened, 
choose another site for injection until the tenderness or “hardening” goes away.  

 
• Tell your doctor about any skin reactions including redness, swelling, or hardening of the 
skin.  

 
• Areas where you may inject Rilonacept Regeneron include the left and right sides of the 
abdomen, and left and right thighs. If someone else is giving you the injection, the upper arms 
may also be used for injection (see Figure 12):  

 
(Do not inject within a 5-cm area around the navel.) 

 
 
 

 
 
 
 
 
 
 
 
 
 
 

 
 

 
Figure 12 

 
2. Choose the area for the injection. Clean the area in a circular motion with a new alcohol wipe. 

Begin at the centre of the site and move outward. Let the alcohol air dry completely. Do not touch 
this area again before injecting. 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

42 

 
3. Hold the syringe in one hand like you would hold a pencil. 
 
4. With the other hand gently pinch a fold of skin around the site that you cleaned for injection. 
 
5. Use a quick “dart like” motion to insert the needle straight into the skin (90° angle) (see Figure 

13a). Do not push down on the plunger while inserting the needle into the skin. For small children 
or persons with little fat under the skin, you may need to hold the syringe and needle at a 45° angle 
(see Figure 13b). 

 
 
 
 
 
 
 
 
 
 
 
 

 
 

 
Figure 13a (Adults) 

 
 
 
 
 
 
 
 
 
 
 
 

 
 
 

Figure 13b (Small Children, Thin Patients) 
 
6. After the needle is completely in the skin, let go of the skin that you are pinching. 
 
7. With your free hand hold the syringe near its base. Gently pull back the plunger. If blood comes 

into the syringe, the needle has entered a blood vessel. Remove the needle, discard the syringe and 
needle. Start over with ‘STEP 1: Setting up for an injection’ using new supplies. 

 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

43 

8. If no blood appears, inject all the medicine in the syringe at a slow, steady rate, pushing the plunger 
all the way down. It may take up to 30 seconds to inject the entire dose. 

 
9. Pull the needle out of the skin, and hold a piece of sterile gauze over the injection site for several 

seconds. 
 
10. Do not replace the needle cover. Throw away the vials, used syringes and needles in the puncture-

resistant container. Do not recycle the container. Do not throw away vials, needles, or syringes in 
the household rubbish. 

 
11. Keep the puncture-resistant container out of reach of children. When the container is about two-

thirds full, dispose of it as instructed by your doctor or pharmacist. 
 
12. Used alcohol wipes can be thrown away in the household rubbish. 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

44 

--------------------------------------------------------------------------------------------------------------------------------
------- 
The following information is intended for medical or healthcare professionals only and is provided as a 
tear-off leaflet:  
 
Indication 
 
Rilonacept Regeneron is indicated for the treatment of Cryopyrin-Associated Periodic Syndromes (CAPS) 
with severe symptoms, including Familial Cold Autoinflammatory Syndrome (FCAS) and Muckle-Wells 
Syndrome (MWS), in adults and children aged 12 years and older. 
 
Posology 
Adults 
Treatment in adults should be initiated with a loading dose of 320 mg. Dosing should be continued with a 
once-weekly injection of 160 mg. Rilonacept Regeneron should not be given more often than once 
weekly.  
 
Paediatric population (12 to 17 years old) 
Treatment should be initiated with a loading dose of 4.4 mg/kg, up to a maximum of 320 mg. Dosing 
should be continued with a once-weekly injection of 2.2 mg/kg, up to a maximum of 160 mg (see Table 
1). Dosing in children must be adjusted as the child grows. The patient or care giver should be advised to 
speak to the treating physician before adjusting the dose. The experience in children is limited. In the 
clinical program for CAPS, 8 adolescents aged 12-17 were treated for up to 18 months. 
 
Paediatric population (up to 12 years old) 
No data are available on the use of Rilonacept Regeneron in children with CAPS under 12 years of age, 
therefore it is not recommended in this paediatric age group. 
 
Elderly (65 years old or older) 
Available data indicate that dose modification is not required based on advanced age. However, clinical 
experience in patients above 65 years is limited, therefore caution is recommended. 
 
Renal impairment 
No dose adjustment is required in patients with mild, moderate or severe renal impairment, or end stage 
renal disease. However, clinical experience in such patients is limited. 
 
Hepatic impairment 
Rilonacept Regeneron has not been studied in patients with hepatic impairment. 
 
Method of administration 
Rilonacept Regeneron is for subcutaneous use only. It is not intended for intravenous or intramuscular use. 
 
The adult loading dose should be administered as two 2 ml subcutaneous injections (320 mg of rilonacept 
in total) given on the same day at different sites.  The subsequent doses are administered as a 2 ml (160 mg 
of rilonacept) subcutaneous injection once a week.  
 
For paediatric patients, the dose is delivered as one or two (for loading dose) subcutaneous injections with 
a maximum single-injection volume of 2 ml. 
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

45 

For convenience, the corresponding dose volume for weekly injection in paediatric patients is presented in 
Table 1 below.  
 
Table 1:  Rilonacept Regeneron dose volume (after reconstitution) by body weight for paediatric patients, 
aged 12-17 years  

Weight range (kg) Dose volume (ml) 
23.6 to 27.2  0.7 
27.3 to 30.8 0.8 
30.9 to 34.4  0.9 
34.5 to 38.1  1 
38.2 to 41.7  1.1 
41.8 to 45.4  1.2 
45.5 to 49.0  1.3 
49.1 to 52.6  1.4 
52.7 to 56.3  1.5 
56.4 to 59.9  1.6 
60.0 to 63.5  1.7 
63.6 to 67.2 1.8 
67.3 to 70.8  1.9 

70.9 or greater 2 
 
Special precautions for storage 
 
Store in a refrigerator. Do not freeze. 
 
Keep the vials in the outer carton in order to protect from light.  
 
After reconstitution, if necessary the product may be kept at room temperature, but should be used within 
three hours of reconstitution because it does not contain a preservative. 
 
Reconstitution and administration instructions 
 
Instructions for reconstitution 
 
Using aseptic technique, Rilonacept Regeneron powder should be reconstituted with 2.3 ml solvent (water 
for injections) prior to administration.  
 
The 2.3 ml of solvent should be withdrawn from the solvent vial attached directly to a 3-ml syringe and 
then injected into the powder vial for reconstitution with 27-gauge, ½-inch needle (to obtain a final 
reconstitution volume of 2.75 ml). The needle and syringe used for reconstitution with solvent should then 
be discarded and should not be used for subcutaneous injections. After the addition of solvent, the vial 
contents should be reconstituted by shaking the vial for approximately one minute and then allowing it to 
sit for one minute. The resulting 80 mg/ml solution is sufficient to allow a withdrawable volume of up to 2 
ml for subcutaneous administration.  
 
The reconstituted solution is viscous, clear and colourless to pale yellow. Prior to injection, the 
reconstituted solution should be carefully inspected for any discolouration or particulate matter. If there is 
discolouration or particulate matter in the solution, the product must not be used.  
 



Me
di
cin

al
 p
ro

du
ct
 n
o 
lo
ng

er
 a
ut

ho
ris

ed

46 

Instructions for administration 
 
Using aseptic technique, the recommended dose volume, up to 2 ml (160 mg) of the solution should be 
withdrawn with a new 27-gauge, ½-inch injection needle attached to a new 3-ml syringe for subcutaneous 
injection.  
 
Sites for subcutaneous injection, such as the abdomen, thigh, or upper arm, should be rotated. Injections 
should never be made at sites that are bruised, red, tender, or hard.  
 
The initial administration of Rilonacept Regeneron by a patient or caregiver should be under the guidance 
of a trained healthcare professional. For subsequent self-administration by patients, appropriate instruction 
in proper injection technique should be provided and ability to apply that technique ascertained.  
 
Disposal 
 
Each vial should be used for a single dose only. The vial should be discarded after withdrawal of the 
solution. 
 
Patients or their caregivers should be instructed on the appropriate procedure for disposal of the vials, 
needles, and syringes. 


	SUMMARY OF PRODUCT CHARACTERISTICS
	A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) ANDMANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
	B. CONDITIONS OR RESTRICTIONS REGARDING SUPPLY AND USE
	C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETINGAUTHORISATION
	A. LABELLING
	B. PACKAGE LEAFLET